|
|
 |
|
Viewing report
|
|
|
|
Next Generation Sequencing: Market Size, Segmentation, Growth and Trends by Provider
DeciBio, Nov 2011, Pages: 124
Next generation sequencing (NGS) is a disruptive technology that allows scientists to sequence millions to billions of short DNA reads for a variety of applications such as whole genome sequencing, or expression profiling. NGS is the fastest growing and the most attractive segments of the $6.5B genomics space. With an estimated market size of ~$1.1B in 2011, and a double digit growth rate, NGS is poised to revolutionize not only medical research in academic laboratories and biopharma, but also the healthcare landscape and applied markets (e.g., food testing, forensics).
This report reviews the market size, segmentation, growth and trends of the NGS (and third generation sequencing) market. We segmented the market by company (Illumina, Life Technologies (SOLiD, Ion Torrent), Roche (454 Life Sciences), Pacific BioSciences, Helicos, Complete Genomics, others), product types (instrument, reagents, services), research setting (research, biopharma, applied markets and clinical), throughput (high and low) and geography (U.S., Europe, Asia/Pacific, other). For each of these segments, we provide an estimate yearly market size and growth from 2007 to 2015, as well as key growth drivers and moderators.
In addition, we review major factors driving future growth including
1) increased reagent usage on current high throughput platforms installed base
2) decentralization via personalized sequencing platforms such as Life Technologies’ PGM that make the technology accessible to individual academic laboratories and in clinical settings
3) adoption of the technology by new customers (e.g., applied markets such as AgBio, patients in clinical trial)
4) increased usage for new scientific applications beyond pure sequencing (e.g., expression profiling, ChIP-Seq, methylation studies)
5) broader adoption of sequencing services (e.g., Complete Genomics, BGI).
On the other hand, we discuss four key factors significantly moderating growth including
1) pricing pressure driven by more affordable instrument options and continued technological improvements leading to cheaper cost per base pair and technology commoditization
2) service providers offering an alternative to in-house platform adoption, as many academic laboratories don’t have the appetite for large capital expenditure for such fast-evolving technologies
3) a lack of bioinformatics infrastructure and tools to make sense of these complex data sets, especially for more translational applications
4) an unfavorable funding environment in the U.S. and EU.
In this first edition, we also place an emphasis on five key topics: 1) next generation sequencing and its emerging adoption in clinical settings 2) the evolution of decentralization driven by personalized sequencing instruments (e.g., PGM, MiSeq), 3) the impact of sequencing service providers 4) exon sequencing and target enrichment opportunities and challenges, and 5) NGS vendor selection criteria and unmet needs.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
